DataSheet2_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.xlsx by Gabriella Gálffy (177759)

“…The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).…”

Design of Benzyl-triazolopyrimidine-Based NADPH Oxidase Inhibitors Leads to the Discovery of a Potent Dual Covalent NOX2/MAOB Inhibitor by Beatrice Noce (16540800)

Subjects:

Measurement of mitochondrial superoxide anion production in HL-1 cells exposed for 12 or 72h to LG, NG, HG or IHG. by Patrick Mordel (17020879)

Differences among the classes of CAMs. by Daniel P. Bradley (10306893)

“…Some <i>N</i>-hydroxypyridinedione (HPD) HBV RNaseH inhibitors significantly reduced accumulation of capsids in HBV-replicating cells. A representative HPD <b>1466</b>, with a 50% effective concentration against HBV replication of 0.25 µM, decreased capsid and core protein accumulation by 50–90% in HepDES19 and HepG2.2.15 cells. …”

The synchronous activity of SGN fiber populations is disrupted and their response to sound is decreased with increasing levels of <i>L</i>_<i>u</i> heterogeneity. by Maral Budak (6680351)

Discovery of Triazolyl Derivatives of Cucurbitacin B Targeting IGF2BP1 against Non-Small Cell Lung Cancer by Fan-Fan Shang (16953264)

Subjects:

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”

Velocity distribution at different openings (a) 25%; (b) 50%; (c) 75%; (d) 100%. by Weiqing Xu (1279959)

Experimental outline. by Melissa A. MacIver (12850566)

Assessment of cell proliferation within the vocal fold muscle following DFATs transplantation. by Ikuo Mikoshiba (9312007)

Subjects:

CONSORT flowchart. by Jaskiran Kaur (160829)

Baseline characteristics of study subjects. by Jaskiran Kaur (160829)

Baseline level biochemical and circulating biomarkers in study subjects. by Jaskiran Kaur (160829)

Change in serum levels of vitamin D and angiogenic marker at 16 weeks follow-up. by Jaskiran Kaur (160829)

Represents the levels of biomarkers as baseline and follow up in placebo and cholecalciferol group. by Jaskiran Kaur (160829)

Effect of the Hill coefficient on estimates of <i>ε</i>_max (left column) and IC₅₀ (right column) for the logistic model with drug applied to the growth rate <... by Hope Murphy (8843516)

Longer polyQ sequences decrease the nuclear localization of AR in the absence of hormone. by Carlos M. Roggero (11909585)

Titanate Nanosheets/Cellulose Composite Showing Improved Crystallinity and Decreased Water Wettability by Gamma-Irradiation by Yaowaluk Tariwong (22630109)

Representative immunohistochemistry images of PCNA expression in renal tissues among CG, NG, NVG, and NVRG (×400). by Jian-feng Li (8667645)